Bioatla to host virtual r&d day to review ba3071 cab-ctla-4 phase 1 data in multiple solid tumor types on wednesday, december 13, 2023

San diego, dec. 06, 2023 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual r&d day on wednesday, december 13, 2023 at 10:00 am et. to register, click here.
BCAB Ratings Summary
BCAB Quant Ranking